Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Section Navigation
			
			CDC Home


Facebook
        Twitter
        LinkedIn
        Syndicate





Hazard ID 5 – Cercopithecine herpesvirus 1 (B Virus) Infection Resulting from Ocular Exposure										Related Pages
										May 1999
DHHS (NIOSH) Publication Number 99-100
cover page - Hazard ID 5-Cercopithecine herpesvirus 1 (B Virus) Infection Resulting from Ocular Exposure
Key Points
Mucocutaneous exposure to biological fluid from macaque monkeys can result in infection with Cercopithecine herpesvirus 1, commonly known as B virus.
Eye splashes appear to be common in the primate industry.
Dendritic corneal lesions characteristic of other ocular herpes virus infections may not be present
All personnel who work with macaques should wear eyewear conforming to established standards for eye and splash protection.
If exposure prevention fails, the adequacy and timeliness of wound or exposure decontamination procedures are critical factors in determining the risk for infection.Description of Hazard
On October 29, 1997, a 22-year-old researcher at a primate-center field station was assisting with a routine group capture of rhesus macaques (*Macaca mulatta*) in a free-ranging corral. Personnel conducting the capture wore uniforms, disposable latex gloves, and surgical masks. Eye protection was not worn. During the transfer of an unidentified macaque into a squeeze cage, undetermined liquid from the animal entered the researchers eye. The worker wiped her eye at the time of exposure. Approximately 45 minutes later she flushed her eye with tap water for 2-3 minutes. There was no medical treatment or consultation at the time of the exposure. The researcher subsequently developed a *Cercopithecine herpesvirus 1* (B virus) infection; despite intensive antiviral therapy, she died on December 10, 1997. This incident is the first documented case of a B virus infection resulting from an ocular exposure to macaque secretions.
On November 8, 1997, the researcher sought medical attention for the first time because the exposed eye was red and swollen. At this time, the emergency department physician specifically looked for dendritic lesions of the cornea that are characteristic of ocular herpes infections. Although dendritic corneal lesions were reported in a previous fatal B virus infection, they were not seen in the present case. On the basis of the reported circumstances of the contact, it was initially concluded that B virus infection was unlikely. This case is reported in the following:
CDC (Centers for Disease Control and Prevention) [1998]. Fatal Cercopithecine herpesvirus 1 (B Virus) Infection Following a Mucocutaneous Exposure and Interim Recommendations for Worker Protection. Morbidity and Mortality Weekly Report (MMWR) 47(49):10731076,1083; December 18, 1998.
About B Virus
B virus infects >70% of surveyed captive adult macaques, but not other nonhuman primates (NHPs). Like humans infected with *Herpesvirus simplex* virus, monkeys infected with B virus have a lifelong infection, with intermittent reactivation and shedding of the virus in saliva, conjunctival fluid, or urogenital secretions. Although virus shedding is more frequent during the mating season (roughly March to June) and when an animal is ill, under stress, or immunosuppressed, there are often no signs of shedding. Macaques should always be regarded as potentially infectious.
There have been approximately 40 known cases of fatal human B virus infection described in the English language literature. Previously reported human infections usually have been attributed to macaque bites or scratches, injuries from needles used near a macaques mucous membranes or central nervous system, or contact with infectious products from the macaques. Incubation periods may be as short as 2 days, but more commonly they are 2 to 5 weeks. Most documented infections have occurred among biomedical research employees who worked with macaques. Laboratory workers handling only infected central nervous system or primary monkey kidney cell lines have also been exposed and, in at least one instance, infected. One case of person-to-person transmission has been reported.
Recommendations for Preventing B Virus Infections
Published recommendations for the prevention and treatment of B virus infections in exposed persons include the following:
CDC (Centers for Disease Control and Prevention) [1987]. Guidelines for the Prevention of *Herpesvirus simiae* (B Virus) Infection in Monkey Handlers. Morbidity and Mortality Weekly Report (MMWR) 36(41):680683, 687689; October 23, 1987.
Holmes GP, et al. [1995]. Guidelines for the Prevention and Treatment of B-Virus Infections in Exposed Persons. Clinical Infectious Diseases 20:421439.
Protective eyewear criteria have been established by the American National Standards Institute (ANSI):
ANSI [1989]. Practice for Occupational and Educational Eye and Face Protection, Z87.11989. American Society of Safety Engineers, Des Plaines, IL.
Actions You Should Take
Preventing worker exposure to biohazardous material is the best protection against infection. All organizations that work with macaques or other NHPs should obtain the documents cited in this report (as well as other guidelines and educational materials) and review the occupational health hazards associated with working with NHPs. Employers should ensure that worker protection programs, policies, and procedures are in place to control infection risks from NHPs. Employers should conduct training and periodic assessments to ensure that worker protection programs are effective. In particular, all employees who come into contact with macaques or macaque tissues should be trained about the risks of B virus and other infections and the importance of preventive measures.
Each institution working with NHPs should develop a written, comprehensive personal protective equipment (PPE) program that clearly identifies the PPE required for each specific task or working area of the facility and addresses training, inspection and maintenance, and periodic assessment of program effectiveness. Mandatory PPE should be selected based on a thorough worksite hazard assessment that considers all work procedures and associated hazards (including biohazards), potential routes of exposure, and potential adverse health outcomes.
Reviews of injuries and biohazard exposures among workers exposed to NHPs suggest that mucocutaneous contact with NHP body fluids is common; in one survey, 16 of 17 contacts with primate body fluids involved ocular exposure. Although the 1987 Centers for Disease Control and Prevention (CDC) *Guidelines for the Prevention of Herpesvirus simiae (B virus) Infection in Monkey Handlers* discourages handling fully awake macaques, macaque handlers should be protected with appropriate eye protection when it is necessary to remove physically active animals from cages. The incident described in this report indicates that proper eye protection should also be mandatory during activities such as entering areas containing macaques, conducting captures, and transporting caged macaques. Other activities that require eye protection should be determined by the hazard assessment. Appropriate protective eyewear selection should be based on a number of factors, including the nature and extent of the hazard, nature of the work, associated degree of risk, and requirements of the individual user. Protective eyewear should meet or exceed the criteria established by ANSI. Eye protection must be comfortable, accommodate the need for corrective lenses (eyeglasses), and be adjustable to ensure a secure fit. It may be necessary to provide several different types, styles, and sizes. Personal eyeglasses are not PPE.
Protective goggles designed for splash protection (available with antifog lenses for humid environments and in models that preserve peripheral vision) should be worn to protect the eyes against splash hazards in combination with a mask designed to protect other mucous membranes. Face shields are commonly considered secondary eye protectors that are worn in combination with protective goggles. Although previous guidelines for the prevention of B virus indicate that face shields may be sufficient, ocular exposures have occurred to workers wearing face shields. In one incident, an animal technician was splashed in the eye with an unknown fluid while wearing a combination surgical mask/face shield during the transfer of a monkey within cages. The “face shield” worn during this exposure, a surgical mask with attached plastic eye shield, did not provide adequate protection. To minimize the potential for mucous membrane exposure, face shields must prevent droplet splashes to the head from running down into the eyes and prevent mucous membrane exposure around the edges (sides, top, and bottom to below the chin). Decisions to use face shields as the sole means for preventing ocular exposure should be made only after full consideration of both the limitations of face shields and Occupational Safety and Health Administration (OSHA) regulations.
If exposure prevention fails, the adequacy and timeliness of wound or exposure decontamination procedures are critical factors determining the risk of infection. Institutions that house or conduct procedures involving macaques or potentially contaminated tissues should develop institution-specific post exposure procedures. Such procedures will ensure appropriate diagnostic testing and infection control. First, animal handlers should be instructed to immediately and thoroughly cleanse all bites, scratches, and/or mucosal surfaces or abraded skin exposed to macaque biologic materials and to report these exposures immediately. Following an eye exposure, existing guidelines recommend immediately flushing the eye for at least 15minutes. Existing guidelines should also be followed for cleansing bites, scratches, or other wounds. Second, post exposure procedures should provide potentially exposed workers with direct and rapid access to local physicians knowledgeable about the infectious risks of exposure to NHPs, hazards of B virus infection, signs and symptoms, and treatment, as well as other biohazards associated with NHPs. These physicians should be available on an on-call basis in the event of an exposure. The employer should ensure that direct access to the knowledgeable consultant is available immediately following exposures and at any time the worker is concerned that potential occupational exposure to B virus may be relevant to worker symptoms. When possible, a veterinarian should assess the clinical and virologic status of the source animal. Post exposure procedures should also include routing diagnostic specimens to the B Virus Research and Resource Laboratory (at Georgia State University in Atlanta).
Medical personnel who evaluate primate handlers with conjunctivitis after an eye exposure to potentially infectious material should be aware that the absence of dendritic lesions of the cornea, like the absence of herpetic skin vesicles, does not reliably rule out B virus infection.
These recommendations will be reviewed and may be revised or augmented following additional consideration by a working group to be convened by the CDC Office of Health and Safety.Acknowledgments
The principal contributors to this publication are Max Kiefer, MS, CIH; Scott Deitchman, MD, MPH; Richard Ehrenberg, MD; and Jerome Flesch, MS, of NIOSH; and Louisa Chapman, MD, MSPH, of the National Center for Infectious Diseases. Desktop publishing provided by Kristina Dragon and Susan Kaelin of NIOSH.
Hazard ID 5 – Cercopithecine herpesvirus 1 (B Virus) Infection Resulting from Ocular Exposurepdf icon [PDF – 52.41 KB]
							
					
						Page last reviewed:  June 6, 2014					Content source: 	National Institute for Occupational Safety and Health homeNIOSH Publications & Products
NIOSH-Issued Publications
Search NIOSHTIC-2 Research Database
Docket
Documents for Public Review
Peer Review Agenda
Databases
eNews
Federal Register Noticesplus icon
FRN Archive 2007-2010
FRN Archive 2005-2006
FRN Archive 2001-2004
FRN Archive 1996-2000
Press Releases and Updatesplus icon
Press Release Archives 2010-2013
Press Release Archives 2006-2009
Press Release Archives 2001-2005
Press Release Archives 1998-2000
Press Release Archives 1992-1997
Regulations
Regulatory Agenda
Science Blog
Software
Video Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue